ATE324371T1 - N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten - Google Patents

N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten

Info

Publication number
ATE324371T1
ATE324371T1 AT02721105T AT02721105T ATE324371T1 AT E324371 T1 ATE324371 T1 AT E324371T1 AT 02721105 T AT02721105 T AT 02721105T AT 02721105 T AT02721105 T AT 02721105T AT E324371 T1 ATE324371 T1 AT E324371T1
Authority
AT
Austria
Prior art keywords
nmda
nonaryl
substituted heterocyclic
nr2b antagonists
nr2b
Prior art date
Application number
AT02721105T
Other languages
English (en)
Inventor
Christopher F Claiborne
John W Butcher
David A Claremon
Brian E Libby
Nigel J Liverton
Peter M Munson
Kevin T Nguyen
Brian Phillips
Wayne Thompson
John A Mccauley
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23034191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE324371(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE324371T1 publication Critical patent/ATE324371T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/06Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
AT02721105T 2001-02-23 2002-02-20 N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten ATE324371T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27110001P 2001-02-23 2001-02-23

Publications (1)

Publication Number Publication Date
ATE324371T1 true ATE324371T1 (de) 2006-05-15

Family

ID=23034191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02721105T ATE324371T1 (de) 2001-02-23 2002-02-20 N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten

Country Status (33)

Country Link
US (2) US7217716B2 (de)
EP (1) EP1379520B2 (de)
JP (1) JP4179879B2 (de)
KR (1) KR100849839B1 (de)
CN (1) CN100567293C (de)
AT (1) ATE324371T1 (de)
AU (1) AU2002252053B2 (de)
BG (1) BG108113A (de)
BR (1) BR0207526A (de)
CA (1) CA2438895A1 (de)
CZ (1) CZ20032258A3 (de)
DE (1) DE60210944T3 (de)
DK (1) DK1379520T3 (de)
EA (1) EA005974B1 (de)
EC (1) ECSP034744A (de)
EE (1) EE200300403A (de)
ES (1) ES2261658T3 (de)
GE (1) GEP20063741B (de)
HR (1) HRP20030669A2 (de)
HU (1) HUP0303258A3 (de)
IL (2) IL157254A0 (de)
IS (1) IS6902A (de)
MX (1) MXPA03007621A (de)
NO (1) NO20033732L (de)
NZ (1) NZ527365A (de)
PL (1) PL364625A1 (de)
PT (1) PT1379520E (de)
SI (1) SI1379520T1 (de)
SK (1) SK10542003A3 (de)
UA (1) UA75392C2 (de)
WO (1) WO2002068409A1 (de)
YU (1) YU64303A (de)
ZA (1) ZA200306159B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1399160A4 (de) * 2001-06-12 2004-08-25 Merck & Co Inc Nr2b-rezeptor-antagonisten zur behandlung oder prävention von migräne
EP1452530A4 (de) * 2001-12-03 2005-11-30 Japan Tobacco Inc Azolverbindung und deren medizinische verwendung
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN1642422A (zh) * 2002-03-15 2005-07-20 西巴特殊化学品控股有限公司 4-氨基嘧啶及其在表面抗菌处理中的应用
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CN1659161A (zh) 2002-04-16 2005-08-24 帝人株式会社 具有ccr3拮抗作用的哌啶衍生物
KR20040104596A (ko) 2002-04-25 2004-12-10 데이진 가부시키가이샤 Ccr3 길항 작용을 갖는 4,4-2치환 피페리딘 유도체
JP2004315511A (ja) * 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Mch受容体アンタゴニスト
PT1648882E (pt) * 2003-06-04 2008-10-20 Merck & Co Inc 3-fluoro-piperidinas como antagonistas de nmda/nr2b
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
JP5032851B2 (ja) 2004-02-03 2012-09-26 アストラゼネカ アクチボラグ キナゾリン誘導体
WO2006017409A2 (en) * 2004-08-03 2006-02-16 Merck & Co., Inc. 1,3-disubstituted heteroaryl nmda/nr2b antagonists
JP2008512417A (ja) * 2004-09-10 2008-04-24 ユセベ ファルマ ソシエテ アノニム シグマ受容体リガンド
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
WO2007003962A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
DE602006013040D1 (de) * 2005-12-21 2010-04-29 Janssen Pharmaceutica Nv Substituierte pyradinon-derivate als alpha2-adrenorezeptor-antagonisten
US7935706B2 (en) 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
BRPI0709699A2 (pt) * 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inibiÇço da toxidez da alfa-sinucleina
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
KR101152162B1 (ko) * 2006-12-08 2012-07-10 에프. 호프만-라 로슈 아게 치환된 피리미딘 및 jnk 조절제로서 그의 용도
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CN101663292A (zh) * 2007-04-23 2010-03-03 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物
AU2008240729B2 (en) 2007-04-23 2012-08-23 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
CA2697256C (en) 2007-08-22 2013-10-15 Astrazeneca Ab Cyclopropyl amide derivatives
WO2009058261A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
CA2711582A1 (en) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ 4−(3−クロロ−2−フルオロアニリノ)−7−メトキシ−6−{[1−(n−メチルカルバモイルメチル)ピペリジン−4−イル]オキシ}キナゾリンのフマル酸塩
RU2502734C2 (ru) 2008-07-03 2013-12-27 Янссен Фармацевтика Нв Замещенные 6-(1-пиперазинил)-пиридазины в качестве антагонистов 5-нт6 рецептора
EP2307374B1 (de) 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituierte-pyridine als schnell dissoziierende dopamin 2-rezeptorantagonisten
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
SG183231A1 (en) * 2010-02-18 2012-09-27 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
JP2013520414A (ja) * 2010-02-18 2013-06-06 アストラゼネカ・アクチエボラーグ シクロプロピルベンズアミド誘導体の新規な結晶形態
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN103582632B (zh) * 2011-03-31 2015-08-19 拜耳知识产权有限责任公司 取代的苯并咪唑
WO2013049119A1 (en) * 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Selective nr2b antagonists
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
JP2016028017A (ja) * 2012-12-13 2016-02-25 大正製薬株式会社 フッ素置換ピペリジン化合物
JP2017001954A (ja) * 2013-11-08 2017-01-05 石原産業株式会社 含窒素飽和複素環化合物
US9856250B2 (en) * 2014-05-28 2018-01-02 Toa Eiyo Ltd. Substituted tropane derivatives
CA2950285A1 (en) * 2014-06-04 2015-12-10 Rugen Holdings (Cayman) Limited Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists
RU2017107558A (ru) * 2014-09-15 2018-10-18 Руджен Холдингс (Кайман) Лимитед Производные пирролопиримидина в качестве антагонистов nmda-рецептора nr2b
WO2016100349A2 (en) * 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
US10584102B2 (en) * 2015-05-11 2020-03-10 Basf Se Process for preparing 4-amino-pyridazines
TWI721987B (zh) * 2015-06-01 2021-03-21 開曼群島商盧郡控股(開曼)有限公司 做為nr2b nmda受體拮抗劑之3,3-二氟哌啶胺基甲酸酯雜環化合物
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
PT3589632T (pt) * 2018-02-23 2020-12-09 Fraunhofer Ges Forschung Novos inibidores de glutaminil ciclases bacterianas para utilização no tratamento de doenças periodontais e relacionadas

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL265777A (de) 1960-06-09
DE2341965C3 (de) 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
WO1984001151A1 (en) * 1982-09-24 1984-03-29 Beecham Group Plc Amino-azabicycloalkyl derivatives as dopamine antagonists
MX24433A (es) 1990-02-06 1993-05-01 Pfizer Derivados de 3-piperidino-1-cromanol y sus analogos y procedimiento para su preparacion
CA2080475C (en) 1990-05-10 2001-04-17 Bertrand Leo Chenard Neuroprotective indolone and related derivatives
US5189036A (en) 1990-06-20 1993-02-23 Schering Ag Imidazolylbenzoyl substituted heterocycles
EP0584192A1 (de) 1991-04-18 1994-03-02 Pfizer Inc. Prodrug-ester von phenolischen 2-piperidino-1-alkanolen
RU2065859C1 (ru) 1991-07-17 1996-08-27 Пфайзер Инк. Производные 2-(4-гидроксипиперидино)-1-алканола и производные 2-(4-гидроксипиперидино)-1-алканона
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
SI9300097B (en) * 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1994014776A2 (en) 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH09503994A (ja) 1993-03-03 1997-04-22 イーライ・リリー・アンド・カンパニー バラノイド
JPH08508030A (ja) 1993-03-18 1996-08-27 メルク シヤープ エンド ドーム リミテツド ベンゾイミダゾール誘導体
AU3138595A (en) 1994-07-20 1996-02-16 Acea Pharmaceuticals, Inc. Haloperidol analogs and the use thereof
US5661161A (en) 1994-09-29 1997-08-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0742208A1 (de) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamid-Derivate
MX9709112A (es) 1995-05-26 1998-02-28 Pfizer Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato.
DE19541264A1 (de) 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
EP0771779B1 (de) 1995-11-06 2002-05-02 Kuraray Co., Ltd. Verfahren zur Herstellung von Acetalen
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
EP0787493A1 (de) 1996-02-03 1997-08-06 F. Hoffmann-La Roche Ag Tetrahydroisochinolin-Derivate
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
WO1997045119A1 (en) 1996-05-24 1997-12-04 Novartis Ag Use of substance p antagonists for treating social phobia
IL128221A (en) 1996-07-25 2003-12-10 Biogen Inc Cell adhesion inhibitors
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0846683B1 (de) 1996-12-03 2001-09-19 F. Hoffmann-La Roche Ag 4-Hydroxypiperidinderivate
FR2758327B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles arylpiperazines derivees de piperidine
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
IT1291569B1 (it) 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
WO1999025685A1 (en) 1997-11-18 1999-05-27 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6020347A (en) 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
DE19815026A1 (de) * 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE69921147T2 (de) 1998-08-07 2005-02-24 Applied Research Systems Ars Holding N.V. Fsh mimetika zur behandlung von infertilität
DE19838300A1 (de) 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
HUP0203338A2 (hu) 1999-04-13 2003-03-28 Abbott Gmbh & Co. Kg Integrin receptor ligandumok
EP1206260A4 (de) 1999-06-30 2002-10-30 Merck & Co Inc Src-kinase hemmende verbindungen

Also Published As

Publication number Publication date
JP4179879B2 (ja) 2008-11-12
CA2438895A1 (en) 2002-09-06
CZ20032258A3 (cs) 2004-01-14
JP2004524314A (ja) 2004-08-12
DE60210944T2 (de) 2007-04-19
EE200300403A (et) 2003-12-15
IL157254A0 (en) 2004-02-19
ECSP034744A (es) 2003-10-28
US20040209889A1 (en) 2004-10-21
AU2002252053C1 (en) 2002-09-12
EA005974B1 (ru) 2005-08-25
IL157254A (en) 2008-11-26
BG108113A (bg) 2005-04-30
DE60210944D1 (de) 2006-06-01
NO20033732D0 (no) 2003-08-22
KR100849839B1 (ko) 2008-08-01
GEP20063741B (en) 2006-02-10
SI1379520T1 (sl) 2006-08-31
HUP0303258A2 (hu) 2004-01-28
NO20033732L (no) 2003-10-22
YU64303A (sh) 2006-05-25
BR0207526A (pt) 2004-03-09
DK1379520T3 (da) 2006-08-21
EP1379520B1 (de) 2006-04-26
PL364625A1 (en) 2004-12-13
IS6902A (is) 2003-07-31
HRP20030669A2 (en) 2005-06-30
CN100567293C (zh) 2009-12-09
DE60210944T3 (de) 2015-07-23
EP1379520A1 (de) 2004-01-14
US20020165241A1 (en) 2002-11-07
CN1503793A (zh) 2004-06-09
UA75392C2 (en) 2006-04-17
HUP0303258A3 (en) 2004-06-28
AU2002252053B2 (en) 2006-09-14
ES2261658T3 (es) 2006-11-16
US7217716B2 (en) 2007-05-15
ZA200306159B (en) 2004-07-05
SK10542003A3 (sk) 2004-03-02
KR20030076703A (ko) 2003-09-26
EP1379520B2 (de) 2014-04-09
EA200300919A1 (ru) 2004-02-26
WO2002068409A1 (en) 2002-09-06
NZ527365A (en) 2005-08-26
MXPA03007621A (es) 2003-12-04
PT1379520E (pt) 2006-08-31
US7053089B2 (en) 2006-05-30

Similar Documents

Publication Publication Date Title
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
ATE440603T1 (de) 8-hydroxychinolinderivate
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
NO20060774L (no) Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer
NO20052182L (no) Nye forbindelser
ATE399770T1 (de) Tachykininrezeptorantagonisten
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
DE60302157D1 (de) Opioidrezeptorantagonisten
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
GB0308201D0 (en) Novel compounds
SE0102057D0 (sv) New Salts I
SE0102058D0 (sv) New Salts II
ATE491709T1 (de) Pyrrolidinohydrochinazoline
ATE338046T1 (de) 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1379520

Country of ref document: EP

REN Ceased due to non-payment of the annual fee